Industry News
Single cell research
Using a water droplet 1 trillion times smaller than a litre of soda as a sort of nanoscale test tube, a University of Washington scientist is conducting chemical analysis and experimentation at unprecedented tiny scales.
[ + ]Avantogen signs license agreement with Hawaii Biotech
Avantogen (ASX:ACU), formerly Australian Cancer Technology, has signed a worldwide, nonexclusive license agreement with Hawaii Biotech to evaluate Avantogen's proprietary adjuvant GPI-0100 with a series of vaccines. [ + ]
Anadis to sell Travelan in USA
Melbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories. [ + ]
Researchers address the meaning of the genomic revolution
Genetics genomics have disturbed science's dreams of explaining human nature and individuality as merely a function of the activity of genes, modulated by environmental factors, according to University of Queensland Federation Fellow Professor Paul Griffiths. [ + ]
AtCor Medical to list on ASX in November
Sydney-based devices company AtCor Medical has lodged its prospectus for an initial public offering (IPO) to raise AUD$15 million for expanding the US marketing and sales of its cardiovascular diagnostic device, SphygmoCor. [ + ]
A wee step forward
Physicists in Singapore have created the first paper battery that generates electricity from urine.
[ + ]Starpharma secures full ownership of VivaGel technology
Melbourne drug developer Starpharma (ASX:SPL) has acquired outright ownership of its VivaGel technology following changes to licence arrangements that were executed when Starpharma was spun-out of the Biomolecular Research Institute (BRI) in 1996. [ + ]
Solbec's managing director resigns
Perth-based Solbec Pharmaceuticals' (ASX:SBP ) managing director, Stephen Carter, has resigned. [ + ]
Money flows back into Australian biotech stocks: Intersuisse
Cash is finally flowing towards biotechnology and medical device stocks after a long and sustained drought, according to Intersuisse biotechnology index for the quarter ended September 2005. [ + ]
Avantogen cancer gene test partnership progressing
A partnership initiated in 2003 between Avantogen (ASX:ACU) (formerly Australian Cancer Technology) and Prof Ursula Kees at Perth's Telethon Institute for Child Health Research is closer to developing a diagnostic test to enable more effective treatment of cancer. [ + ]
SciGen signs US$145m hep B distribution deal
Singapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac. [ + ]
Medical Developments International appoints new CEO
Melbourne-based Medical Developments International (ASX:MVP, MDI) has appointed Dr Simon Fisher as its new CEO, starting today. [ + ]
ChemGenex pinpoints inflammation gene
Diabetes- and oncology-gene hunter ChemGenex Pharmaceuticals (ASX:CXS) now has solid evidence that a particular variant of the SEPS-1 gene, already identified as a trigger for Type 2 diabetes, is a strong risk factor for a broad range of chronic inflammatory disorders. [ + ]
General requirements for testing and calibration
ISO/IEC 17025:2005 is now available. It specifies the general requirements for the competence to carry out tests and/or calibrations, including sampling. It covers testing and calibration performed using standard methods, non-standard methods, and laboratory-developed methods.
[ + ]Creation of the National Biosecurity Centre
The Vice-Chancellor of La Trobe University, Professor Michael Osborne, has welcomed the announcement by the Victorian government that funding has been dedicated to commence establishment of the National Biosecurity Centre in Victoria.
[ + ]